Medidata Expands Agreement With Worldwide Clinical Trials
Expanded relationship will utilize Medidata’s artificial intelligence solutions.
Medidata and Worldwide Clinical Trials have announced an expansion of their existing relationship. The new agreement will implement Medidata AI, enabling Worldwide to further reduce trial timelines and improve site selection.1
“Worldwide will accelerate clinical research and advance the life sciences industry by leveraging site-level granularity and real-time actionable observations provided by Medidata AI’s turnkey solution,” Tom Doyle, chief technology officer, Medidata, said in a press release.
"For over 10 years, we’ve partnered with Medidata to help our customers gather advanced, data-driven insights so they can make confident and well-informed decisions about the future direction of their clinical trials,” Peter Benton, president and CEO, Worldwide Clinical Trials said in the press release. “Incorporating Medidata AI Intelligent Trials into our studies will allow us to more systematically plan, design, and execute research so we can deliver a better experience for patients and sponsors.”
Medidata AI appeared in the news earlier this year as well, when Medidata renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc. A key element of this collaboration is the evolution of PPD TrueCast, a business solution powered by Medidata AI, which combines patient recruitment and site performance data to deliver predictive models and advanced analytics.2
In addition to Medidata AI, the new agreement with PPD featured the Medidata Platform, Medidata Adjudicate, and additional Medidata Rave product offerings. The duo has been working together on clinical studies for biopharmaceutical and medical device companies since 2009.
References
1. Medidata Selected by Worldwide Clinical Trials to Accelerate Trials and Transform Patient Experience. News release. May 14, 2024. Accessed May 14, 2024. https://www.3ds.com/newsroom/press-releases/medidata-selected-worldwide-clinical-trials-accelerate-trials-and-transform-patient-experience
2. Medidata and Thermo Fisher Scientific’s PPD Clinical Research Business Collaborate to Accelerate Clinical Trials Innovation. News release. February 28, 2024. Accessed May 14, 2024. https://www.medidata.com/en/about-us/news-and-press/medidata-and-thermo-fisher-scientifics-ppd-clinical-research-business-collaborate-to-accelerate-clinical-trials-innovation/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
